Tema Obesity & Cardiometabolic ETF (HRTS)
| Assets | $75.78M |
| Expense Ratio | 0.75% |
| PE Ratio | 34.02 |
| Shares Out | 2.24M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | n/a |
| Volume | 15,189 |
| Open | 33.24 |
| Previous Close | 33.50 |
| Day's Range | 33.00 - 33.33 |
| 52-Week Low | 26.26 |
| 52-Week High | 35.58 |
| Beta | 0.86 |
| Holdings | 47 |
| Inception Date | Nov 20, 2023 |
About HRTS
Fund Home PageThe Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.
Top 10 Holdings
43.33% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 5.61% |
| Vertex Pharmaceuticals Incorporated | VRTX | 5.52% |
| Amgen Inc. | AMGN | 5.41% |
| Novo Nordisk A/S Class B | NOVO B.CO | 5.16% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 5.07% |
| DexCom, Inc. | DXCM | 3.63% |
| Cytokinetics, Incorporated | CYTK | 3.55% |
| Insulet Corporation | PODD | 3.35% |
| Edwards Lifesciences Corporation | EW | 3.21% |
| Chugai Pharmaceutical Co Ltd | 4519.T | 2.82% |
News
Looking at Next Gen of Weight Loss: Tema ETFs CEO
Tema Obesity & Cardiometabolic ETF (HRTS) currently holds 46 companies focused on GLP-1, obesity, and weight-loss. Tema ETFs CEO and Founder Maurits Pot says we're trying to build a product that goes ...
Fighting Obesity Using ETFs
Weight loss has long been a challenge for many people, me included. Indeed, there are an estimated 1 billion individuals living with obesity, and the Obesity World Atlas estimates this could rise to 1...
What's Next for Weight Loss Stocks?
Tema Obesity & Cardiometabolic ETF is up 4% year-to-date. David Song discusses health care and ETF investing.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Sign of top or next pop? Rush of new offerings spring up around Mag 7, weight loss
Sign of top or next pop? Rush of new offerings spring up around Mag 7, weight loss.
Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund
Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk and Eli Lilly , aiming to tap into growing demand for their weight-loss and diabetes drugs.